• Home
The News Universe
No Result
View All Result
No Result
View All Result
The News Universe
No Result
View All Result

TurboGen Advances in the American Market: Signs LOI for System Installation with New US Client

admin by admin
September 4, 2024
in Uncategorized
0

September 4, 2024 – TurboGen (TASE: TURB), a leader in developing advanced solutions for local energy production, is pleased to announce today that it has signed a letter of intent (LOI) with a US client for the supply and installation of the company’s micro-turbine systems (one or more) to generate energy for the client’s facilities. The LOI, signed on September 2, 2024, represents a significant step in expanding the company’s operations in the US market and in promoting TurboGen’s innovative “Energy as a Service” model.

Yaron Gilboa, CEO of TurboGen: “The signing of this LOI marks another significant milestone in our global expansion. The growing demand for efficient and sustainable energy solutions in the US market underscores the need for TurboGen’s technology. We believe that our ‘Energy as a Service’ model will allow customers to benefit from our technology while reducing costs and increasing energy efficiency.”

This announcement follows a number of TurboGen’s recent successes, including the first installation of a commercial system in New York City and the completion of successful trials at Technion laboratories, confirming the hydrogen combustion capabilities of the company’s systems.

About TurboGen:

TurboGen (TASE: TURB) specializes in developing advanced solutions for local energy production in buildings and various facilities. The company’s innovative technology is designed to provide efficient, reliable, and environmentally friendly energy solutions, addressing the growing global demand for distributed electricity generation.

For more information about the company: https://turbogenchp.com

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: TurboGen
Contact Person: Investor Relations
Email: Send Email
City: Petah Tikva
Country: Israel
Website: turbogenchp.com/

Previous Post

Multiple Sclerosis Market Assessment 2034 | Multiple Sclerosis Therapies, FDA Approval, Clinical trials, Prevalence, Treatment Algorithms and Companies by DelveInsight | Immune Response BioPharma

Next Post

Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Amylyx Pharma, Ionis Pharma, Annexon, Inc., UniQure Biopharma, Sangamo Therapeutics

Next Post

Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Amylyx Pharma, Ionis Pharma, Annexon, Inc., UniQure Biopharma, Sangamo Therapeutics

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.